Yes @antibotter ... with a comment like this at the bottom of the article, I would start to get a little worried if AstraZeneca don't even mention AZD0466 at this conference ?If AZD0466 is not mentioned IMO it would 'appear' on the surface that it is not a big priority for AstraZeneca at present?? If they do speak about it then happy days for SPL
José Baselga, Executive Vice President, Research & Development, Oncology, said: “We will be sharing some of our latest research at the 2019 AACR Annual Meeting, including 28 new molecular entities and six combinations, highlighting an exciting new phase of scientific discovery from our Oncology R&D.”
Yes @antibotter ... with a comment like this at the bottom of...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.82M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |
